Pulmonology Xagena

Xagena Mappa
Xagena Newsletter

Patients with severe, uncontrolled asthma: Tezepelumab has reduced exacerbations across all seasons - A post hoc analysis of the PATHWAY phase 2b study

Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin ( TSLP ), an epithelial cytokine implicated in airway inflammation in asthma, from binding to its heterodimeric receptor.

A post hoc analysis of the PATHWAY study has evaluated the effect of Tezepelumab on asthma exacerbations on a seasonal basis.

Adults ( n=550 ) with severe, uncontrolled asthma were randomized 1:1:1:1 to receive subcutaneous Tezepelumab 70 mg every 4 weeks ( Q4W ), 210 mg Q4W or 280 mg every 2 weeks ( Q2W ), or placebo Q2W, for 52 weeks.

The annualized asthma exacerbation rate ( AAER ), total number of days with an exacerbation, proportion of patients with at least one exacerbation or 0, 1 or greater than or equal to 2 exacerbations, and proportion of patients experiencing an exacerbation per day were evaluated by season and over the year, by treatment in the overall study population and in subgroups according to baseline blood eosinophil count ( greater than or equal to 300 cells/µL or less than 300 cells/µL ) or atopic asthma status ( fluoro-enzyme immunoassay [ FEIA ]+ or FEIA- ).

Seasonal variations in exacerbation rates were found, with peaks observed in fall and winter, and greater variations in patients with high blood eosinophil counts ( greater than or equal to 300 cells/µL ).

Tezepelumab treatment has consistently reduced exacerbation rates across all seasons compared with placebo.

Furthermore, there was a trend, which was not significant, toward a reduction in the total number of days with exacerbations and in the proportion of patients with exacerbations during each season in patients treated with Tezepelumab compared with those who received placebo, irrespective of blood eosinophil count or atopic asthma status.

In conclusion, Tezepelumab has reduced exacerbations across all seasons, irrespective of evaluated baseline disease characteristics.
These data support the efficacy of Tezepelumab in a broad population of patients with severe, uncontrolled asthma.( Xagena )

Corren J et al, J Asthma Allergy 2021;14:1-11